# Halozyme Therapeutics (HALO) — News

HALO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/halo/news

## Recent headlines

- [Payward-Saldo deal seen closing in 2027](https://www.ainvest.com/news/payward-saldo-deal-closing-2027-2610) — AInvest Wire, Oct 14, 2026
  The anticipated merger between Payward and Saldo, two prominent players in the digital payments sector, is expected to finalize in 2027, according to recent regulatory filings and internal communications from both companies. The deal, which has been under review by antitrust authorities since early…
- [Halozyme Therapeutics, Inc.: TD Cowen raises target price to $130 from $105](https://www.ainvest.com/news/halozyme-therapeutics-td-cowen-raises-target-price-130-105-2610) — AInvest Wire, Oct 13, 2026
  TD Cowen has raised its price target for Halozyme Therapeutics, Inc. (HALO) to $130 from $105, reflecting positive outlook on HALO . HALO, which develops and commercializes drug-device combination products using advanced auto-injector technology, has seen its stock price rise in recent trading…
- [Havoc awarded SBIR phase III contract by Army Applications Laboratory for multi-domain mission collaborative autonomy](https://www.ainvest.com/news/havoc-awarded-sbir-phase-iii-contract-army-applications-laboratory-multi-domain-mission-collaborative-autonomy-2610) — AInvest Wire, Oct 12, 2026
- [ActiveOps - Expects double digit adj EBITDA growth and increased PBT for H1 FY27](https://www.ainvest.com/news/activeops-expects-double-digit-ebitda-growth-increased-pbt-h1-fy27-2610) — AInvest Wire, Oct 12, 2026
  ActiveOps PLC (LON:AO), a global provider of AI-powered decision intelligence solutions for service operations, has indicated expectations of double-digit adjusted EBITDA growth and an increase in pre-tax profit (PBT) for the first half of fiscal year 2027 (H1 FY27). The company has not yet…
- [Argenx SE shares up 4.7%](https://www.ainvest.com/news/argenx-se-shares-4-7-2610) — AInvest Wire, Oct 9, 2026
  Argenx SE (NASDAQ: ARGX) shares rose 4.7% on October 9, 2026, following continued momentum in the biotechnology sector and positive investor sentiment surrounding the company’s commercial performance. The stock is currently trading at $818.63, with a 52-week range of $661.85 to $1,072.75. The…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).